Tempus AI has expanded its multi-year collaboration with Merck to enhance AI-driven biomarker discovery and precision medicine, particularly in oncology. As part of this partnership, Merck will gain access to Tempus’ de-identified multimodal datasets through the Lens Platform and Workspaces, which utilize GPU-backed tools for advanced analyses in areas such as biomarker discovery, resistance research, and early drug-combination development. This alliance signifies a deeper integration of AI tools in early-stage oncology drug discovery, aimed at improving treatment outcomes.
Tempus AI expands partnership with Merck for precision medicine research
